On September 26, 2019, Dr. Wang Pin was appointed as Chief Science Officer (CSO) of Simcere, and will be in charge of Simcere’s innovative medicine R&D strategy and foreign strategic cooperation, recruitment of top talents for innovative medicine, and organizational capacity building. Dr. Wang Pin will also have direct leadership over cell and gene therapy business of Simcere, and prepare to build Simcere’s Boston Innovation Center and establish the “State Key Laboratory of Translational Medicine and Innovative Medicine”.
Dr. Wang Pin, CSO, Simcere
Ren Jinsheng, Chairman of Simcere, said, “Dr. Wang Pin has profound research experience and abundant academic achievements in cancer immunity, cell and gene therapy and other innovative fields. He has also successfully established many start-up biotechnology companies. We believe that Dr. Wang Pin’s participation will further enhance the strength of Simcere’s R&D team and help Simcere enter a new strategic stage of innovative medicine research and development.”
Dr. Wang said, “I am honored to have the opportunity to join Simcere. I am inspired by its forward-looking layout and vision in innovative areas to embark on a new journey of exploration. I am also looking forward to working with Simcere's management and R&D team to develop the next-generation effective medicine and advanced therapies to help more patients!”
Biography of Dr. Wang Pin
Dr. Wang graduated with his Bachelor's degree from the University of Science and Technology of China, later he got his doctoral degree and engaged in post-doctoral research at California Institute of Technology. Before joining Simcere, he was Director of the Center for Immune Engineering, tenured professor of the Chemical Engineering and Materials Science Department, Zohrab A. Kaprielian Fellow of the School of Engineering, professor of the Department of Biomedical Engineering and Department of Pharmacology and Pharmacy at the University of Southern California, USA.
Dr. Wang has many years of research experience in biotechnology. He has published more than 100 academic papers in top international magazines with H index 37. He has also won many awards, such as Viterbi’s Best Research Award of the Year.
He is co-founder of many start-ups, including Immune Design, which was co-founded with Professor David Baltimore, a Nobel Prize winner in life sciences. The firm was merged by MSD in 2018 after its successful listing.